DUOGASTRONE® direct healing of duodenal ulcer

Trials suggest*

- radiological disappearance of ulcer crater
- relief of symptoms within a few days
- superiority over antacid or anticholinergic therapy

- patients can lead a normal life
- special diets are unnecessary
- even chronic cases, with a long history of symptoms, respond

Unique 'positioned release' capsules deliver the active ingredient (50 mg carbenoxolone sodium) into the duodenum.


* Further trials are in progress to study the effects of DUOGASTRONE in long-term therapy



Full information available on request from


Berk Pharmaceuticals Limited Godalming Surrey England Made under licence from Biorex Laboratories Ltd., London. Brit. Pat. Nos. 843,133 & 1,093, 286

Read. Trade Mark



No nourishment here . . .

. . . unless an adequate supply of pancreatic enzymes is available to complete digestion.




Pancrex V is the most effective preparation for replacing pancreatic secretion in the gut. It is indicated in cystic fibrosis of the pancreas, chronic pancreatitis, pancreatectomy, post-cholecystectomy and in all digestive disorders where a relative deficiency of pancreatic enzymes

is a contributory factor. Pancrex V is activated, whole dried pancreas


having a tryptic activity approximately equal to 5 times that of Pancreatin B.P.

Pancrex V

References: Diseases of Children (1964), Blackwell, Oxford. Diseases of Infancy and Childhood. 8th Edn. (1962), Churchill, London. Lancet (1960) 1, 365. Brit. Med. J. (1958), 2, 1039




APERCUT: meedlled suitures




ior easy penetration amd beititer

meedle control



Reverse cutting point affords easy initial penetration of tough tissue



Taper body provides smooth passage through tissue and minimises trauma

The TAPERCUT needled suture has been designed primarily for use in Cardiovascular surgery. A sharp reverse cutting edge extends 18" back from the point of the needle. The remainder of the needle then blends into a taper cross section. This gives the balance of three sharpened edges and affords easy penetration of tough tissue with reduced trauma and better needle control.

The TAPERCUT needled suture is highly efficient in sclerotic vessel suturing, vascular and valvular prostheses implants and bronchial stump closure. But its use is not limited to Cardiovascular surgery alone. It is a valuable aid in tendon repair, Gastro-Intestinal, Plastic, Paediatric, Thoracic or Neuro Surgery. TAPERCUT needles are attached to Mersilene and Chromic Catgut. Available in foil overwrap

P.O. Box 408, Bankhead Avenue, Edinburgh EH11 4HE

- 12 packs per carton.

*Trade Mark

Colofac

The first specific antispasmodic for the gastrointestinal tract



Gut spasm dyspepsia/abdominal pain

Presentation and basic NHS cost: Bottles of 100 and 600 sugar coated tablets each containing 50 mg. mebeverine HCI at 25/- and 146/-.

Further information is available on request,
The CROOKES Laboratories Limited, Basingstoke, Hampshire.

Any programme designed to reduce distress or mortality in ULCERATIVE COLITIS would need to

- 1. Secure Early Detection.
- 2. Provide Specific Treatment.
- 3. Provide Flexible Treatment.
- 4. Prevent Relapse.



Early Detection



It is now commonly recognized that the most dangerous period for a patient with ulcerative colitis is the year of his first attack. Early detection is important for another reason as well. With proper management such cases can usually avoid surgery. 1. In order to obtain early hospital referrals an extensive campaign detailing the condition is being brought to the attention of general practitioners by the originators and manufacturers of Salazopyrin, the drug of proven efficacy and documented safety in the treatment of ulcerative colitis.



Specific Treatment

"Whereas...many drugs have been administered with diverse successes, the one accepted drug is (Salazopyrin)....most patients tolerate the drug well, and improvement such as reduction of bowel movements and recession of bleeding generally occurs within a week or 10 days." 2-

The mode of action of Salazopyrin remains unknown. Its success is undoubtedly due to its specific affinity for connective tissues, particularly the colonic submucosa.

Within two or three days treatment with Salazopyrin, the number of stools decreases, abdominal pains disappear, the fever subsides and the appetite improves. 3.

In fulminating ulcerative colitis successful results are reported with the use of Salazopyrin and steroids in combination. However, as steroids are essentially suppressive rather than curative, mild and moderate acute attacks are best treated with Salazopyrin alone.

Dosage for the Acute Attack.

2 to 4 tablets (1 g. to 2 g.) four to six times daily. The dosage should be adjusted according to the patient's needs. This is decreased to the maintenance dose (2 g. daily) as the patient improves. At any indication of a relapse, however, the dosage should be increased to the maximum tolerated level.

- 1. Postgrad. Med. 1960, 28, 157.
- "Chronic Ulcerative Colitis" Charles C. Thomas (Publisher), Springfield, Illinois, 1969, p 45.
- 3. "Gastroenterology" Vol. fi. W. B. Saunders Co. Philadelphia 1964, p 863.



Flexible Treatment

Salazopyrin (sulphasalazine) is available as plain 0.5 g. tablets, as the 0.5 g. EN-tabs and as 0.5 g. suppositories. The EN-tab is enteric coated, and of an ovoid shape for easy swallowing. It has been specifically designed for the patient who may exhibit gastrointestinal intolerance to the plain tablet and who is on long term therapy.

"(Salazopyrin) incorporated into a suppository... has recently been shown by controlled trial to exert a beneficial topical action if inserted nightly in patients with distal proctocolitis, 15 of 18 patients receiving potent suppositories going into clinical remission as compared with 5 of 18 treated by inert suppositories. No side effects were observed."

Illustration 1— plain 0.5g. tablet.

Illustration 2— 0.5g. EN-tab.

Illustration 3— 0.5g. suppository.



Side effects and Precautions:

Side effects may consist of gastrointestinal upset which usually resolves upon change to the enteric-coated tablets. Very rare instances of agranulocytosis have been reported.

It is contraindicated in patients with a history of marked sensitivity to sulpnonamides.

Salazopyrin should be administered under constant medical supervision, including periodic blood examinations. The usual precautions for sulphonamide therapy should be exercised. If serious symptoms occur, including leukopoenia or sensitization, the drug should be discontinued immediately. There is no specific antidote for Salazopyrin.



Prevention of relapse

"As long-term treatment for ulcerative colitis corticosteroids are disappointing."2

"Salazopyrin has been shown to reduce the relapse rate greatly when used in a maintenance dosage of 0.5 g. q.d.s. over the period of 1 year". As it has been reported that "out of every five patients who respond to medical treatment of a first attack of ulcerative colitis, four have a second attack within 12 months" 3, the efficacy of Salazopyrin in the long-term treatment of the ulcerative colitis patient, is clear.

"This is the first demonstration in a formal trial that any treatment reduces the relapse rate in ulcerative colitis... it therefore appears preferable to systemic corticosteroids, for this purpose. 24 (out of 34) patients remained in symptomatic remission for a year while taking 2 g. of Salazopyrin daily whereas only 8 (out of 33) remained symptom free in the placebo group.

22 out of the 24 patients on Salazopyrin who remained in remission at the end of the trial had a non-haemorrhagic mucosa which, in many cases, appeared normal.

... only 3 patients out of 34 had to discontinue treatment because of side-effects. In the patients treated with Salazopyrin, there was no difference in the haemoglobin level before and after treatment; but the mean white-cell count was lower after 6 months or a year than at the start of the treatment, though in no patient was it less than 4500 per c. mm.''3

Proven Maintenance Therapy: 2 tablets twice a day.


- 1. Postgrad. Med. J. 1968, 44, 699.
- 2. Brit. med. J. 1968, 2, 539, 605.
- **3.** Lancet, 1965, i 185.

SALAZOPYRIN°

Literature and detailed information on Salazopyrin are available on request.



Paramount House, 75 Uxbridge Road, Ealing, London W.5, Telephone: 01-579 0102/7






The Radiochemical Centre Amersham England

for inside information

Accurate early diagnosis of gastric diseases is enormously simplified by the use of the Olympus range of gastrocameras and fiberscopes. With the Olympus gastrocameras all the main anatomical features of the stomach interior can be photographed, and also directly observed, and biopsies and cytological examinations can be carried out, too.



Olympus Gastro Fiberscope Model GFB, for biopsy examination under direct visual control. The process can be simultaneously photographed for records.

Olympus Gastrocamera with Fiberscope Model GTFa, direct endoscopic observation and colour photography by the unique intra-gastric camera of the gastric mucous membrane.
Olympus Gastrocamera Model GTVa, reaches the so-called 'blind' areas of the

Olympus Oesophageal Fiberscope EFS, for observation and photography of walls of the oesophagus, plus biopsy.

gastric mucosa.

Other models include the Olympus Gastro Fiberscope Model GFS, observation and sequence photography. Olympus Gastro Fiberscope Model GFC for cytological gastric examination.

And other special purpose gastrocameras.

All supplied complete with accessories. Projector, recording facilities available. Gastro cameras in the U.K. serviced quickly by trained Air-Shields personnel. 'Phone now for demonstration or technical literature.

AIR SHIELDS(U.K.)LIMITED

Towerfield Estate, Shoeburyness, Southend-on-Sea, Essex. Telephone: Shoeburyness 2294/5.

BIOGASTRONE

Specific healing effect

'Carbenoxolone has a specific effect, facilitating healing of gastric ulcer, and is not merely yet another symptomatic measure'. *Brit med J,* 1965, **2**: 1274

Patients remain up and about

'It is the only drug therapy for gastric ulcer which has been demonstrated conclusively to accelerate healing, which can be achieved with patients remaining up and about, often at work, with minimum change in diet'. *Gut*, 1965, **5**:19

conclusively shown to heal gastric ulcers

without bed rest or dietary restrictions

Tablets of 50 mg carbenoxolone sodium. Please write for full prescribing information.



Berk Pharmaceuticals Limited Godalming Surrey England

NEW PRODUCT ANNOUNCEMENT

Duphalac ends the laxative era

"The constant use of purgatives by the lay public to induce a regular daily habit, which is commonly believed necessary for good health, may decrease the sensitivity of the intestinal mucous membranes so that larger doses have to be taken and the bowel fails to respond to normal stimuli. Thus the development of a normal habit is prevented."

Martindale's Extra Pharmacopoeia The Pharmaceutical Press, London 25th Edition (1967) p. 1266

Now there is Duphalac - a non-laxative treatment for habitual constination. Unlike many traditional laxatives, which goad the bowel musculature into fitful action, non-laxative Duphalac has no direct effect either on the smooth muscle or its innervation. Duphalac changes the environment within the colon to achieve normal bowel movement and a softening of the stool.

How does it work?

Duphalac is a synthetic disaccharide which is not appreciably absorbed after oral ingestion. It reaches the colon unchanged and serves as a nutrient for saccharolytic bacteria. Their increased activity causes a change of the colonic environment and a lowered pH in the colon. The clinical result is that normal defaecation is restored.


The clinician's verdict

One double-blind comparison of Duphalac with placebo involved 52 "truly constipated" patients. The success rate was 80% for Duphalac against 33% for placebo. "The difference in success rate is highly significant (P < 0.01)". The author described Duphalac as "a completely harmless substance" (Gut, 1968, 9:84)

Duphalac is presented as a syrup containing lactulose 50% w/w, lactose 5% w/w, galactose 8% w/w, in bottles of 200 ml. and 2 litres. Further information will be supplied on request.

Duphalac non-laxative treatment for habitual constipation






Nitrogen Loss can be fatal following surgery, trauma, burns or infection

Supplied as crystal-clear solution, complete with sterile infusion set, containing –all the pure, essential aminoacids in balanced proportions. –sorbitol, for carbohydrate provision.

- -minerals.
- -vitamins.



Full information from



SELPHARM LABORATORIES LTD., Percival House · Pinner Road, Harrow · Middlesex

Published July 1969

Automation and Data Processing in Pathology

Symposium organized by The College of Pathologists
Edited by Professor T. P. Whitehead

CONTENTS

Automatic scanning for cervical smears	A. I. SPRIGGS
Automation in diagnostic bacteriology	R. E. O. WILLIAMS and R. E. TROTMAN
Serological techniques	C. E. D. TAYLOR
Multichannel continuous flow analysis on t	he SMA-4/-7A M. G. NESON
An evaluation of the Coulter model S	D. F. BARNARD, A. B. CARTER, J. CROSLAND-TAYLOR and J. W. STEWART
Automated blood group serology	GEOFFREY H. TOVEY
Continuous-flow techniques for tests in clin	ical chemistry D. W. NEILL and J. R. DOGGART
Discrete analysis systems	B. E. NORTHAM
Computer operations and the structure of i	nformation E. G. KNOX
The laboratory and patient records	W. W. HOLLAND
Problems and benefits of using a computer	for laboratory data processing
	F. V. FLYNN
Data processing in histopathology	M. K. ALEXANDER
Basis of data control for anatomical pathol	ogy J. CHANDLER SMITH
Analysis of hospital bacteriological data	R. M. STIRLAND, VALERIE F. HILLIER, and M. G. STEYGER
Computers in bacteriology	P. H. A. SNEATH
A data processing system for haematology	D. G. CHALMERS
Computer processing of biochemical inform	nation without going on-line
	I. D. P. WOOTTON
Experience with on-line computing in clinic	
	L. G. WHITBY and D. SIMPSON
Concluding remarks	M. J. R. HEALY

PRICE 30s. (U.S.A. \$3.75) including postage This publication can be ordered now from

The Publishing Manager, JOURNAL OF CLINICAL PATHOLOGY B.M.A. House, Tavistock Square, London, W.C.1, or through any leading bookseller

WORLD MEDICAL PERIODICALS

(Reprint Third Edition 1961)

THIS IMPORTANT REFERENCE BOOK for authors, editors, librarians, medical schools, research laboratories, publishers, and booksellers has been reprinted in response to great demand. It gives details of over 5,800 journals of medicine, pharmacy, dentistry and veterinary medicine, which are listed alphabetically and indexed by subject and by country. Each entry gives the title in the original form. In addition, translations have been added to Japanese titles, and transliterations to Greek and Cyrillic titles (the latter in accordance with The Transliteration of Russian, Serbian and Bulgarian for Bibliographical Purposes, issued by the Royal Society, London).

476 pages, Royal 8vo, cloth bound

Price 42s. (U.S.A. \$5.25), including postage

and its SUPPLEMENT

This Supplement brings the Third Edition of World Medical Periodicals fully up to date. It gives details of some 700 journals which have either first appeared or changed their title since 1961, the year of publication of the Third Edition.

80 pages, Royal 8vo, cloth bound

Price 20s. (U.S.A. \$2.50), including postage

Published 1 July. Copies can be ordered direct from

The Publishing Manager
BRITISH MEDICAL JOURNAL

B.M.A. House, Tavistock Square, London, W.C.1 or through leading booksellers

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Volume 4, No. 6, 1969

Contents

Review: P. Rödbro: Human Gastric Intrinsic Factor Secretion	473
D. S. Miller, M. A. Rahman, R. Tanner, V. I. Mathan, & S. J. Baker: The Vascular Architecture of the Different Forms of Small Intestinal Villi in the Rat (Rattus norvegicus)	477
W. Nienstedt & K. Hartiala: Steroid Metabolism by the Canine Intestine: I. Qualitative Experiments with Progesterone	483
A. Penttila & J. Hirvonen: Identity of the Basally Located Parietal and Enterochromaffin-like Cells of the Rat Gastric Mucosa	489
S. Emås & M. I. Grossman: Response of Heidenhain Pouch in Histamine, Gastrin, and Feeding before and after Truncal Vagotomy in Dogs	497
A. Flatmark, B. Fretheim & E. Gjone: Early Colectomy in Severe Ulcerative Colitis	505
A. Berstad & H. Petersen: A Comparison between the Effects of Secretin and Histamine on the Gastric Secretion of Pepsin in Man	511
K. Fischermann, I. Bech & B. Andersen: Diagnostic Value of the Augmented Histamine Test in Cancer of the Upper Part of the Stomach	517
M. Isokoski, K. Krohn, K. Varis & M. Siurala: Parietal Cell and Intrinsic Factor Antibodies in a Finnish Rural Population Sample	521
D. Andersen: The Use of Central Venous Pressure Measurement in the Diagnosis of Major Arterial Bleeding in Gastroduodenal Haemorrhage	529
V. Salupere: Gastric Biopsy in Peptic Ulcer: A Follow-up Study	537
G. D. Cain, P. Moore, Jr., M. Patterson & M. A. McElveen: The Stimulation of Lactase by Feeding Lactase	545
Announcement	551

Issued October 1969

THE SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY publishes original papers in gastroenterology and pertinent fields of nutrition. Each issue contains about 80 pages; eight issues form one yearly volume. Supplements are supplied free of charge to subscribers. The subscription price including postage is N. kr. 150.-(\$25.-) payable in advance.

Editorial Correspondence

Manuscripts should be addressed to the managing editor. The Scandinavian Journal of Gastroenterology has no objection to the reproduction of short passages and illustrations from this journal without further formality than acknowledgement of the source.

Business Communications

Business communications, including subscriptions and orders for reprints or advertisements, should be sent to the publishers.

Publishers UNIVERSITETSFORLAGET P.O. Box 307, Blindern, Oslo 3 Norway

BIOLOGIE ET GASTRO-ENTÉROLOGIE



Publication des Archives Françaises des maladies de l'appareil digestif

Starting in 1968, the "Archives Françaises des maladies de l'appareil digestif" publish two numbers a year entitled "Biologie et Gastro-entérologie" devoted to reports on experimental work in gastro-enterology carried out in the new research units of the various French University Hospital Centres.

BIOLOGY AND GASTRO-ENTEROLOGY publishes the results of biological and experimental research on the gastrointestinal tract and associated organs.

Original articles are of two kinds: New reports. Original observations.

In each number the review publishes accounts of contemporary French work in the field of gastro-enterology (research projects, preliminary results, summaries of publications). In this way it hopes to give quickly concise and up-to-date information on the research trends in gastro-enterology.

SOME ARTICLES

Incorporation du radiosulfate dans les tissus du rat normal ou soumis à la contrainte, par M. O. LAMBERT.

Activité phospholipasique A¹ et A² des sucs pancréatiques d'homme, de rat et de chien. Effet activateur de la trypsine, par M. O. BELLEVILLE.

Exploration radioisotopique de la circulation collatérale portale, par P. O. Pelikan.

Temps de transit et calibre de l'intestin grêle chez l'homme: Mesure par la courbe de dilution d'un colorant au cours d'une perfusion intestinale de solutés isotoniques de NaCl et de Kcl, par M. O. MATUCHANSKY.

Effet chez l'homme de l'acidification duodénale sur la sécrétion gastrique histaminiques et gastrinique (pentagastrine), par M. O. HANCY.

Régénération cellulaire dans la muqueuse gastrique du chien sous l'effet de divers stimulants et de diverses drogues ulcérigènes, par M. O. GERARD.

The subscribers of ARCHIVES FRANÇAISES DES MALADIES DE L'APPAREIL DIGESTIF receive these supplements as part of their subscriptions.

Subscription (2 numbers) 1969: France F.22. Other countries F. 27

Specimen copy available on application to:

MASSON & CIE - Editeurs. 120 Boulevard Saint Germain, 75-PARIS 6°